CDR March 4th, 2024
Chris W. David, CPA/ABV, ASA
HealthValue Group Managing Partner | Healthcare FMV Expert | Speaker | Member AHLA
Healthcare Roundtable Webinar: Current Trends and What to Expect in 2024?
The Mintz healthcare law group will hold a roundtable discussion focusing on the latest state healthcare transaction review developments. Gain insights into state laws, procedural intricacies, and practical tips on navigating the transaction review process. The event kicks off?on March 20th at 12PM?ET // 9AM PT. Speakers for this event include Lois Johnson , Daniel Cody , Deborah Daccord
?Register here:?https://bit.ly/3Ii1LV1?
Navigating Compliance: Ensuring Proper Documentation with Independent Contractors?
The latest McGuireWoods LLP series, “Ounce of Prevention,” focuses on ensuring compliance with federal healthcare laws regarding financial relationships with independent contractors.?
Failure to properly structure and document these relationships can lead to violations of the Anti-Kickback Statute (AKS) and Stark Law. Specifically, contracts must be in writing, cover services at fair market value, and be signed by both parties to avoid legal risks.?
Providers are advised to implement mechanisms for tracking contracts, conduct periodic audits, and promptly obtain missing signatures.?
Credit top healthcare attorneys Gretchen Townshend and Timothy Fry for these helpful tips.
View the full article here:??https://bit.ly/3STLaeW?
Understanding Regulatory Pressures: 2024 Healthcare Deals Webcast
Sheppard Mullin Richter & Hampton LLP and America’s Physician Groups?invite you to join an insightful discussion on navigating increased scrutiny for healthcare deals in 2024.?
Explore the regulatory challenges healthcare systems and stakeholders face, potential consequences, and tensions between reimbursement models and transactional pullbacks.?
Moderated by Eric Klein from?Sheppard Mullin, panelists include experts from?America’s Physician Groups Bill Barcellona , John Carroll , Jordan Grushkin of Sheppard Mullin Richter & Hampton LLP and Chris P. and Karl Rebay of Moss Adams Join the discussion?on March 5, 2024, to stay informed.?Register here:?https://bit.ly/49RQfeC?
领英推荐
Texas Medical Community Shaken by Pharmacy Kickback Scheme Indictment?
Ten physicians and executives, including podiatrists and local business people, have been indicted in a pharmacy kickback scheme in Texas.?
Allegedly, the physicians were bribed to direct prescriptions to certain pharmacies in return for referral kickbacks. The scheme involved concealing payments through various entities and individuals. The indictment details how kickbacks were facilitated through the use of management service organizations (MSOs).?The scheme was exposed through recordings of meetings discussing payments and tracking prescriptions. The physicians face charges that include conspiracy to violate the Travel Act, bribery, and money laundering.?
Read more here:?https://bit.ly/437a5Aw?
Healthcare Fraud Remains Primary Source for DOJ Recoveries
Healthcare fraud remains the top source of recoveries for DOJ, accounting for almost 70%, or $1.8 billion, of the $2.68 billion total. These recoveries came from insurance companies, hospitals, healthcare groups, diagnostic companies, pharmacies, and physicians. The health law group at Morgan Lewis breaks down the DOJs annual announcement of FCA recoveries here:??https://bit.ly/3wEFfDf
At-Home Cancer Genetic Tests and a New Zealand Shell Company
California man perpetrated a kickback and bribery scheme with testing companies and, telemedicine providers, and marketing companies. To conceal the scheme, the testing companies wired various kickback payments to a shell company in New Zealand, which the defendant controlled. To further conceal the scheme, the fraudster entered into a sham contract with the New Zealand shell company, which made it appear that at least one of the “marketing” companies was legit.?https://bit.ly/3TlnFgl
What Does “Induce” Mean under the AKS?
The Pharmaceutical Coalition for Patient Access (PCPA) recently lost an appeal in the United States District Court for the Eastern District of Virginia. The PCPA challenged a negative opinion issued by the OIG, stating that pharmaceutical manufacturers offering cost-sharing subsidies to Medicare Part D beneficiaries via PCPA could be liable under the Federal health care program Anti-Kickback Statute (AKS).? Two attorneys from Sheppard Mullin Richter & Hampton LLP ’s Healthcare Practice Group break down and analyze this ruling by focusing on the meaning and implication of the word “inducement” in the context of the AKS.?John Tilton? Michael Sutton
Read more here:?https://bit.ly/49Cfhia